GoHealth (GOCO) Q1 2025 earnings summary

Executive summary

• Q1 2025 net revenues increased 19.1% year-over-year to $221.0 million, driven by strong internal agent performance, product expansion, and operational execution.

• Adjusted EBITDA rose 56.4% to $42.1 million, with margin expanding to 19.0% from 14.5% year-over-year, reflecting improved profitability and cost optimization.

• Net loss improved to $9.8 million from $21.3 million in Q1 2024, reflecting enhanced operating leverage and revenue growth.

• Submissions grew 40.2% to 303,026, primarily due to internal captive agent contributions and technology investments.

• Launched GoHealth Protect, expanding into guaranteed acceptance life insurance and diversifying revenue streams.

Financial highlights

• Net revenues: $221.0 million (Q1 2025) vs. $185.6 million (Q1 2024), up 19.1%.

• Adjusted EBITDA: $42.1 million (Q1 2025) vs. $26.9 million (Q1 2024), up 56.4%.

• Net loss: $9.8 million (Q1 2025) vs. $21.3 million (Q1 2024), a 54% improvement.

• Direct operating cost per submission decreased 18.4% year-over-year to $522.

• Net cash used in operating activities was $12.4 million in Q1 2025, compared to net cash provided of $12.5 million in Q1 2024.

Outlook and guidance

• Management expects GoHealth Protect to ramp up in Q2 and Q3 2025, contributing meaningfully to full-year results.

• Anticipate a disruptive AEP in Q4 2025 due to health plan margin management and benefit repricing, leading to increased consumer shopping activity.

• No specific full-year revenue guidance provided due to market uncertainties; focus remains on flexibility and capital efficiency.

• Substantial doubt exists about the company's ability to continue as a going concern due to liquidity constraints and upcoming debt maturities.